• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

    9/26/24 6:00:00 AM ET
    $AXNX
    Medical/Dental Instruments
    Health Care
    Get the next $AXNX alert in real time by email

    Axonics, Inc. (NASDAQ:AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence.

    The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15®) and is paired with the same tined lead and intuitive, easy to use patient remote control. The R20 also provides physicians and their patients with enhanced programming capabilities and expanded MRI labeling.

    "Approval of the Axonics R20 is welcome news for Australians with bladder and bowel dysfunction," said Dr. Janelle Brennan, a urologist at St. John of God Bendigo Hospital. "I am excited to offer my patients a therapy that provides durable symptom relief with a small rechargeable neurostimulator that can last over 20 years in the body."

    Axonics commenced SNM commercial activities in Australia in March 2023. In May 2024, Axonics received regulatory approval from the TGA to market its F15® recharge-free SNM system. In Australia, Axonics also markets Bulkamid®, the company's unique hydrogel indicated for female stress urinary incontinence.

    "We are delighted to receive regulatory approval for our latest rechargeable SNM system in Australia," said Raymond W. Cohen, chief executive officer. "Our mission-driven team remains committed to innovating, supporting our dedicated physician customers and their patients, and raising awareness of our best-in-class incontinence therapies."

    Axonics expects to commence sales of the R20 to Australian customers in November.

    About Axonics

    Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas after being ranked No. 1 in 2022.

    Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company's best-in-class urethral bulking hydrogel, Bulkamid, provides safe and durable symptom relief to women with stress urinary incontinence. Moderate to severe incontinence affects tens of millions of adults globally. For more information, visit www.axonics.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like "may," "will," "likely," "should," "expect," "anticipate," "future," "plan," "believe," "intend," "goal," "seek," "endeavor," "estimate," "project," "continue," and variations of such words and similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: Axonics' ability to consummate the transactions contemplated by the Agreement and Plan of Merger, dated January 8, 2024 (the "Merger Agreement"), by and among Axonics, Boston Scientific Corporation ("Boston Scientific"), and Sadie Merger Sub, Inc., a wholly owned subsidiary of Boston Scientific ("Merger Sub"), providing for the merger of Merger Sub with and into Axonics with Axonics continuing as the surviving company and a wholly owned subsidiary of Boston Scientific (the "Merger"), in a timely manner or at all; the risk that the Merger Agreement may be terminated in circumstances requiring the payment by Axonics of a termination fee; the satisfaction (or waiver) of the conditions to the closing of the Merger; potential delays in consummating the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to termination of the Merger Agreement; Axonics' ability to timely and successfully realize the anticipated benefits of the Merger; the ability to successfully integrate the businesses of Axonics and Boston Scientific; the effect of the announcement or pendency of the Merger on Axonics' current plans, business relationships, operating results and business generally; the effect of limitations placed on Axonics' business under the Merger Agreement; significant transaction costs and unknown liabilities; litigation or regulatory actions related to the Merger Agreement or Merger; FDA or other U.S. or foreign regulatory or legal actions or changes affecting Axonics or Axonics' industry; the results of any ongoing or future legal proceedings, including the litigation with Medtronic, Inc., Medtronic Puerto Rico Operations Co., Medtronic Logistics LLC and Medtronic USA, Inc. (the "Medtronic Litigation"); any termination or loss of intellectual property rights, including as a result of the Medtronic Litigation; introductions and announcements of new technologies by Axonics, any commercialization partners or Axonics' competitors, and the timing of these introductions and announcements; changes in macroeconomic and market conditions and volatility, including the risk of recession, inflation, supply chain constraints or disruptions and rising interest rates; and economic and market conditions in general and in the medical technology industry specifically, including the size and growth, if any, of Axonics' markets, and risks related to other factors described under "Risk Factors" in other reports and statements filed with the U.S. Securities and Exchange Commission ("SEC"), including Axonics' most recent Annual Report on Form 10-K, which is available on the investor relations section of Axonics' website at www.axonics.com and on the SEC's website at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

    The forward-looking statements included in this press release are made only as of the date of this press release, and except as otherwise required by federal securities law, Axonics does not assume any obligation nor does it intend to publicly update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240926828469/en/

    Get the next $AXNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXNX

    DatePrice TargetRatingAnalyst
    1/9/2024Outperform → Peer Perform
    Wolfe Research
    7/19/2023$69.00Outperform
    Robert W. Baird
    7/13/2023$70.00Overweight
    KeyBanc Capital Markets
    5/23/2023$75.00Buy
    CL King
    4/14/2023$75.00Buy
    Mizuho
    3/24/2023$71.00Hold → Buy
    Needham
    10/21/2022$85.00Outperform
    RBC Capital Mkts
    10/12/2022$75.00Hold
    Jefferies
    More analyst ratings

    $AXNX
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific Announces Results for Fourth Quarter and Full Year 2023

      MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for the period, compared to $0.45 a year ago.

      1/31/24 6:30:00 AM ET
      $AXNX
      $BSX
      Medical/Dental Instruments
      Health Care
    • Axonics Reports Third Quarter 2023 Financial Results

      Generated quarterly revenue of $93.1 million, an increase of 32% year over year Fiscal year 2023 revenue guidance increased to $362 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2023. "Our commercial team continues to execute at a high level, generating over 30% revenue growth in the third quarter," said Raymond W. Cohen, chief executive officer. "Our growth was driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts. Based on the s

      10/30/23 4:01:00 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Axonics to Report Third Quarter 2023 Financial Results on October 30

      Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axonics 3Q23 registration. For those not planning to ask a question, the company recommends accessing the conference call by webcast at the following link: Axonics 3Q23 webcast. A replay of the webcast will be archived in t

      10/2/23 6:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AXNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Boston Scientific Closes Acquisition of Axonics, Inc.

      MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisiti

      11/15/24 8:43:00 AM ET
      $AXNX
      $BSX
      Medical/Dental Instruments
      Health Care
    • Axonics Reports Third Quarter 2024 Financial Results

      Axonics, Inc. (NASDAQ:AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024. "Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year," said Raymond W. Cohen, chief executive officer. "Revenue growth for both sacral neuromodulation and Bulkamid® was driven by higher utilization at existing customers and the onboarding of new accounts." Mr. Cohen continued, "Our commitment to innovation, quality, direct-to-consumer advertising and providing str

      11/7/24 4:01:00 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

      Axonics, Inc. (NASDAQ:AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15®) and is paired with the same tined lead and intuitive, easy to use patient remote control. The R20

      9/26/24 6:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Axonics Modulation downgraded by Wolfe Research

      Wolfe Research downgraded Axonics Modulation from Outperform to Peer Perform

      1/9/24 6:49:41 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Robert W. Baird initiated coverage on Axonics Modulation with a new price target

      Robert W. Baird initiated coverage of Axonics Modulation with a rating of Outperform and set a new price target of $69.00

      7/19/23 7:13:39 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • KeyBanc Capital Markets initiated coverage on Axonics Modulation with a new price target

      KeyBanc Capital Markets initiated coverage of Axonics Modulation with a rating of Overweight and set a new price target of $70.00

      7/13/23 7:29:51 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)

      4 - Axonics, Inc. (0001603756) (Issuer)

      11/15/24 9:00:20 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)

      4 - Axonics, Inc. (0001603756) (Issuer)

      11/15/24 9:00:14 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Director Snyderman Nancy Lynn Md returned $1,061,024 worth of shares to the company (14,944 units at $71.00), closing all direct ownership in the company (SEC Form 4)

      4 - Axonics, Inc. (0001603756) (Issuer)

      11/15/24 9:00:06 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

      SC 13G/A - Axonics, Inc. (0001603756) (Subject)

      2/13/24 4:59:03 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

      SC 13G/A - Axonics, Inc. (0001603756) (Subject)

      2/12/24 12:03:27 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

      SC 13G/A - Axonics, Inc. (0001603756) (Subject)

      2/9/24 8:35:54 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Axonics Inc.

      15-12G - Axonics, Inc. (0001603756) (Filer)

      11/25/24 9:05:44 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Axonics Inc.

      EFFECT - Axonics, Inc. (0001603756) (Filer)

      11/21/24 12:15:05 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • SEC Form 25-NSE filed by Axonics Inc.

      25-NSE - Axonics, Inc. (0001603756) (Subject)

      11/15/24 2:23:54 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

      Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced that Raymond W. Cohen has joined the board of directors as a new independent board director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725221367/en/Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire) Brian Webster, President & CEO of Kestra said, "Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commer

      7/25/24 8:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors

      BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors. Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry. He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX), an Irvine, Calif. based global medical technology company that he co-founded in 2013 and took public in October 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

      12/27/23 8:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Axonics Announces CFO Retirement and Appoints Successor

      Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice president of finance and accounting, will succeed Mr. Dearen on Monday, October 2. "On behalf of the Axonics team and the board of directors, I want to thank Dan, my co-founder and longtime colleague, for his many contributions to the company over the last 10 years," said Raymond W. Cohen, chief executive officer. "Dan has played an instrumental role in Axonics' success and the significant value that

      8/21/23 6:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care